Prognostic factors and the role of interleukin-1 in bacteremia caused by Pseudomonas aeruginosa

Japanese Journal of Chemotherapy

Volumn 58, Issue 5, 2010, Pages 547-554

  Horino, Tetsuya ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bacteremia; Interleukin 1 (IL 1); Prognostic factor; Pseudomonas aeruginosa

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; INTERLEUKIN 1; STREPTOMYCIN;

ACUTE LEUKEMIA; ADULT; ARTICLE; BACTEREMIA; CHRONIC KIDNEY DISEASE; FEMALE; HUMAN; HYPOALBUMINEMIA; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PSEUDOMONAS AERUGINOSA; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 77957686903     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Munoz P, Cruz A F, Rodriguez-Creixems M, Bouza E: Gram-negative bloodstream infections. Int J Antimicrob Agents 2008; 32(Suppl 1): S104
2. Vidal F, Mensa J, Almela M, Martinez J A, Marco F, Casals C, et al: Epidemiology and outcome of Pseudomonas aeruginosa bacteremia with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156: 2121-6
3. Bisbe J, Gatell J M, Puig J, Mallolas J, Martinez J A, Jimenez de Anta M T, et al: Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 1988; 10: 629-35
4. Kang C I, Kim S H, Kim H B, Park S W, Choe Y J, Oh M D, et al: Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37: 745-51
5. Cheong H S, Kang C I, Wi Y M, Ko K S, Chung D R, Lee N Y, et al: Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteremia. Eur J Clin Microbiol Infect Dis 2008; 27: 1219-25
6. Micek S T, Lloyd A E, Ritchie D J, Reichley R M, Fraser V J, Kollef M H: Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-11
7. Gomez J, Alcantara M, Simarro E, Martinez B, Ruiz J, Guerra B, et al: Pseudomonas aeruginosa bacteremia: clinical and epidemiological patterns and treatment. Rev Esp Quimioter 2002; 15: 360-5
8. Lodise T P Jr, Patel N, Kwa A, Graves J, Furuno J P, Graffunder E, et al: Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51: 3510-5
9. Iversen B G, Brantsaeter A B, Aavitsland P: Nationwide study of invasive Pseudomonas aeruginosa infection in Norway: importance of underlying disease. J Infect 2008; 57: 139-46
10. Parkins M D, Gregson D B, Pitout J D, Ross T, Laupland K B: Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection 2010; 38: 25-32
11. Kang C I, Kim S H, Park W B, Lee K D, Kim H B, Kim E C, et al: Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia. Clin Microbiol Infect 2005; 11: 415-8
12. Brun-Buisson C, Doyon F, Carlet J: Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 1996; 154: 617-24
13. Wiest R, Rath H C: Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut Best Pract Res Clin Gastroenterol 2003; 17: 397-425
14. Berg R D: Bacterial translocation from the gastrointestinal tracts of mice receiving immunosuppressive chemotherapeutic agents. Curr Microbiol 1983; 8: 285-92
15. Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, et al: Adverse effects of tumour necrosis factor in cyclophosphamide-treated mice subjected to gut-derived Pseudomonas aeruginosa sepsis. Cytokine 1997; 9: 763-9 (Pubitemid 27477721)
16. Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, et al: Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 1998; 42: 2853-7
17. Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, et al: Paradoxical synergistic effects of tumour necrosis factor and interleukin 1 in murine gut-derived sepsis with Pseudomonas aeruginosa. Cytokine 1999; 11: 366-72 (Pubitemid 29233970)
18. Aliaga L, Mediavilla J D, Llosa J, Miranda C, Rosa-Fraile M: Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2000; 19: 871-4
19. Tsay R W, Siu L K, Fung C P, Chang F Y: Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2002; 162: 1021-7
20. Hung P P, Lin Y H, Lin C F, Liu M F, Shi Z Y: Chryseobacterium meningosepticum infection: antibiotic susceptibility and risk factors for mortality. J Microbiol Immunol Infect 2008; 41: 137-44
21. Elting L S, Rubenstein E B, Rolston K V, Bodey G P: Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-59
22. McKenzie F E: Case mortality in polymicrobial bloodstream infections. J Clin Epidemiol 2006; 59: 760-1
23. Pittet D, Li N, Wenzel R P: Association of secondary and polymicrobial nosocomial bloodstream infections with higher mortality. Eur J Clin Microbiol Infect Dis 1993; 12: 813-9 (Pubitemid 24001419)
24. Abraham E, Laterre P F, Garbino J, Pingleton S, Butler T, Dugernier T, et al: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29: 503-10
25. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351: 929-33
26. Panacek E A, Marshall J C, Albertson T E, Johnson D H, Johnson S, MacArthur R D, et al: Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F (ab′) 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32: 2173-82
27. Rice T W, Wheeler A P, Morris P E, Paz H L, Russell J A, Edens T R, et al: Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006; 34: 2271-81
28. Opal S M, Fisher C J Jr, Dhainaut J F, Vincent J L, Brase R, Lowry S F, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-24
29. Fisher C J Jr, Dhainaut J F, Opal S M, Pribble J P, Balk R A, Slotman G J, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-43
30. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson R C: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550-2 (Pubitemid 120015108)
31. Vogels M T, Hermsen C C, Huys H L, Eling W M, van der Meer J W: Roles of tumor necrosis factor alpha granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice. Infect Immun 1994; 62: 2065-70
32. Silver G M, Gamelli R L, O'Reilly M, Hebert J C: The effect of interleukin 1 alpha on survival in a murine model of burn wound sepsis. Arch Surg 1990; 125: 922-5 (Pubitemid 20218812)
33. Campanile F, Binaglia L, Boraschi D, Tagliabue A, Fioretti M C, Puccetti P: Antibacterial resistance induced by recombinant interleukin 1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream. Cell Immunol 1990; 128: 250-60 (Pubitemid 20225567)
34. Horino T, Matsumoto T, Uramatsu M, Tanabe M, Tateda K, Miyazaki S, et al: Interleukin-1-deficient mice exhibit high sensitivity to gut-derived sepsis caused by Pseudomonas aeruginosa. Cytokine 2005; 30: 339-46
35. Tanabe M, Matsumoto T, Shibuya K, Tateda K, Miyazaki S, Nakane A, et al: Compensatory response of IL-1 gene knockout mice after pulmonary infection with Klebsiella pneumoniae. J Med Microbiol 2005; 54: 7-13
36. Horino T, Matsumoto T, Ishikawa H, Kimura S, Uramatsu M, Tanabe M, et al: Interleukin-1 deficiency in combination with macrophage depletion increases susceptibility to Pseudomonas aeruginosa bacteremia. Microbiol Immunol 2009; 53: 502-11
37. Tsai W C, Strieter R M, Mehrad B, Newstead M W, Zeng X, Standiford T J: CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 2000; 68: 4289-96
38. Van Rooijen N, Kors N, vd Ende M, Dijkstra CD: Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res 1990; 260: 215-22
39. Puneet P, Yap C T, Wong L, Lam Y, Koh D R, Moochhala S, et al: SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 2010; 328: 1290-4
40. Berthelot P, Attree I, Plesiat P, Chabert J, de Bentzmann S, Pozzetto B, et al: Genotypic and phenotypic analysis of type III secretion system in a cohort of Pseudomonas aeruginosa bacteremia isolates: evidence for a possible association between O serotypes and exo genes. J Infect Dis 2003; 188: 512-8
41. Harrison E M, Carter M E, Luck S, Ou H Y, He X, Deng Z, et al: Pathogenicity islands PAPI-1 and PAPI-2 contribute individually and synergistically to the virulence of Pseudomonas aeruginosa strain PA 14. Infect Immun 2010; 78: 1437-46